Form 8-K - Current report:
SEC Accession No. 0001213900-25-054315
Filing Date
2025-06-13
Accepted
2025-06-13 16:30:07
Documents
14
Period of Report
2025-06-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 4.01: Changes in Registrant's Certifying Accountant
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0245506-8k_inmed.htm   iXBRL 8-K 41800
2 AMENDMENT TO STANDBY EQUITY PURCHASE AGREEMENT, DATED AS OF JUNE 13, 2025, BY AN ea024550601ex10-1_inmed.htm EX-10.1 13485
3 LETTER FROM MARCUM LLP, DATED JUNE 12, 2025, ADDRESSED TO THE SECURITIES AND EXC ea024550601ex16-1_inmed.htm EX-16.1 4116
  Complete submission text file 0001213900-25-054315.txt   234717

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inm-20250612.xsd EX-101.SCH 3020
5 XBRL LABEL FILE inm-20250612_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE inm-20250612_pre.xml EX-101.PRE 22363
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0245506-8k_inmed_htm.xml XML 3671
Mailing Address 1445-885 WEST GEORGIA ST. VANCOUVER A1 V6C 3E8
Business Address 1445-885 WEST GEORGIA ST. VANCOUVER A1 V6C 3E8 (604) 669-7207
InMed Pharmaceuticals Inc. (Filer) CIK: 0001728328 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-39685 | Film No.: 251047058
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)